AR064012A2 - Composiciones y combinaciones de activador(es) del receptor de activacion de proliferacion peroxismal (ppar) e inhibidor(es) de absorcion de esterol el uso de dichas composiciones para la manufactura de un medicamento para el tratamiento para indicaciones vasculares diabetes obesidad o reduccion de - Google Patents

Composiciones y combinaciones de activador(es) del receptor de activacion de proliferacion peroxismal (ppar) e inhibidor(es) de absorcion de esterol el uso de dichas composiciones para la manufactura de un medicamento para el tratamiento para indicaciones vasculares diabetes obesidad o reduccion de

Info

Publication number
AR064012A2
AR064012A2 ARP070105283A ARP070105283A AR064012A2 AR 064012 A2 AR064012 A2 AR 064012A2 AR P070105283 A ARP070105283 A AR P070105283A AR P070105283 A ARP070105283 A AR P070105283A AR 064012 A2 AR064012 A2 AR 064012A2
Authority
AR
Argentina
Prior art keywords
compositions
objective
combinations
manufacture
absorption inhibitor
Prior art date
Application number
ARP070105283A
Other languages
English (en)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26950511&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR064012(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of AR064012A2 publication Critical patent/AR064012A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A61K31/055—Phenols the aromatic ring being substituted by halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proveen composiciones y combinaciones terapéuticas que incluyen: (a) al menos un activador del receptor de activacion de proliferacion peroxisomal; y (b) al menos un inhibidor de absorcion de esterol de beta-lactama sustituido o azetidinona sustituida. Una composicion que comprende: (a) un compuesto representado por la formula (2) o una sal o solvato farmacéuticamente aceptable del mismo; (b) monohidrato de lactosa; (c) celulosa microcristalina; (d) povidona; (e) croscarmelosa sádica; (f) lauril sulfato sodico; y (g) estearato de magnesio, con la condicion de que la composicion no comprende: Ingrediente Porcentual en Peso de Ingrediente Compuesto de formula (2) 10 Monohidrato de lactosa 55 Celulosa microcristalina 20 Povidona 4 Croscarmelosa sádica 8 Lauril sulfato sodico 2 Estearato de magnesio 1 Total 100 También se describe el uso de dichas composiciones y combinaciones para la manufactura de un medicamento utiles para el tratamiento de enfermedades vasculares, diabetes, obesidad y reduccion de los niveles de plasma de esteroles.
ARP070105283A 2001-01-26 2007-11-28 Composiciones y combinaciones de activador(es) del receptor de activacion de proliferacion peroxismal (ppar) e inhibidor(es) de absorcion de esterol el uso de dichas composiciones para la manufactura de un medicamento para el tratamiento para indicaciones vasculares diabetes obesidad o reduccion de AR064012A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26439601P 2001-01-26 2001-01-26
US32383901P 2001-09-21 2001-09-21

Publications (1)

Publication Number Publication Date
AR064012A2 true AR064012A2 (es) 2009-03-04

Family

ID=26950511

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP020100269A AR033855A1 (es) 2001-01-26 2002-01-25 Composiciones y combinaciones de activador(es) del receptor de activacion de proliferacion peroxis0mal (ppar) e inhibidor(es) de absorcion de esterol, el uso de dichas composiciones o combinaciones para la manufactura de un medicamento para el tratamiento para indicaciones vasculares, diabetes, obes
ARP070105283A AR064012A2 (es) 2001-01-26 2007-11-28 Composiciones y combinaciones de activador(es) del receptor de activacion de proliferacion peroxismal (ppar) e inhibidor(es) de absorcion de esterol el uso de dichas composiciones para la manufactura de un medicamento para el tratamiento para indicaciones vasculares diabetes obesidad o reduccion de

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP020100269A AR033855A1 (es) 2001-01-26 2002-01-25 Composiciones y combinaciones de activador(es) del receptor de activacion de proliferacion peroxis0mal (ppar) e inhibidor(es) de absorcion de esterol, el uso de dichas composiciones o combinaciones para la manufactura de un medicamento para el tratamiento para indicaciones vasculares, diabetes, obes

Country Status (33)

Country Link
US (5) US20020151536A1 (es)
EP (2) EP1353696B1 (es)
JP (4) JP4777602B2 (es)
KR (1) KR100596257B1 (es)
CN (1) CN100509058C (es)
AR (2) AR033855A1 (es)
AT (2) ATE348649T1 (es)
AU (1) AU2002247019C1 (es)
BR (1) BR0206654A (es)
CA (3) CA2562982C (es)
CL (1) CL2004001174A1 (es)
CY (2) CY1108000T1 (es)
CZ (2) CZ301871B6 (es)
DE (2) DE60216890T2 (es)
DK (2) DK1413331T3 (es)
EC (1) ECSP11004702A (es)
ES (2) ES2290562T3 (es)
HK (2) HK1056696A1 (es)
HU (2) HUP0303915A3 (es)
IL (3) IL156445A0 (es)
ME (1) MEP27808A (es)
MX (1) MXPA03006725A (es)
NO (1) NO331512B1 (es)
NZ (1) NZ525921A (es)
PL (1) PL208110B1 (es)
PT (2) PT1353696E (es)
RS (2) RS51449B (es)
RU (1) RU2356550C2 (es)
SI (2) SI1353696T1 (es)
SK (2) SK288217B6 (es)
TW (1) TWI337083B (es)
WO (1) WO2002058732A2 (es)
ZA (1) ZA200305693B (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR035739A1 (es) * 2001-01-26 2004-07-07 Schering Corp Composiciones farmaceuticas y combinaciones terapeuticas que comprenden secuestrante (s) de los acidos biliares y de inhibidor (es) de la absorcion de los esteroles y el uso de dichas composiciones para la manufactura de un medicamento para el tratamiento de indicaciones vasculares
AU2002240050A1 (en) * 2001-01-26 2002-08-06 Schering Corporation Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications
AU2002336609B2 (en) * 2001-09-21 2006-08-24 Merck Sharp & Dohme Corp. Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
EP1465667A4 (en) 2001-09-24 2007-06-27 Merck & Co Inc SCREENING AND SELECTION PROCEDURE FOR STATIN COMBINATIONS
GB0215579D0 (en) 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
US7135556B2 (en) * 2002-07-19 2006-11-14 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
AR040588A1 (es) 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
EP2283838A3 (en) * 2002-09-27 2011-04-20 Martek Biosciences Corporation Docosahexaenoic acid for treating subclinical inflammation
KR101072909B1 (ko) * 2002-12-16 2011-10-17 깃세이 야쿠힌 고교 가부시키가이샤 경구고형의약
WO2004069193A2 (en) * 2003-02-03 2004-08-19 Thomas Jefferson University Methods and compositions for inhibiting cholesterol uptake
JP4589919B2 (ja) 2003-03-07 2010-12-01 シェーリング コーポレイション 高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用
US7235543B2 (en) 2003-03-07 2007-06-26 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
JP2005015434A (ja) * 2003-06-27 2005-01-20 Kotobuki Seiyaku Kk 血清コレステロール低下剤或はアテローム性硬化症の予防又は治療剤
US20050096307A1 (en) * 2003-11-05 2005-05-05 Schering Corporation Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
CA2543596A1 (en) * 2003-11-07 2005-05-26 Jj Pharma, Inc. Hdl-boosting combination therapy complexes
AU2004303742B2 (en) 2003-12-23 2008-06-19 Astrazeneca Ab Diphenylazetidinone derivatives possessing cholesterol absorption inhibitory activity
EP1723414A4 (en) * 2004-01-16 2008-03-26 Merck & Co Inc NPC1L1 (NPC3) AND METHOD FOR IDENTIFYING ITS LIGANDS
US20070116645A1 (en) * 2004-02-03 2007-05-24 Steven Farber Methods and compositions for inhibiting cholesterol uptake
US7803838B2 (en) * 2004-06-04 2010-09-28 Forest Laboratories Holdings Limited Compositions comprising nebivolol
ATE493973T1 (de) 2004-06-04 2011-01-15 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
US7838552B2 (en) 2004-06-04 2010-11-23 Forest Laboratories Holdings Limited Compositions comprising nebivolol
CN1759834B (zh) * 2004-09-17 2010-06-23 中国医学科学院医药生物技术研究所 黄连素或其与辛伐他汀联合在制备用于预防或治疗与血脂有关疾病或症状的产品中用途
US7524831B2 (en) * 2005-03-02 2009-04-28 Schering Corporation Treatments for Flaviviridae virus infection
UY29607A1 (es) 2005-06-20 2007-01-31 Astrazeneca Ab Compuestos quimicos
SA06270191B1 (ar) 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
AR057072A1 (es) 2005-06-22 2007-11-14 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto
EP1741427A1 (en) * 2005-07-06 2007-01-10 KRKA, D.D., Novo Mesto Pharmaceutical composition comprising simvastatin and ezetimibe
AU2006270047A1 (en) * 2005-07-18 2007-01-25 Reliant Pharmaceuticals, Inc. Treatment with azetidinone-based cholesterol absorption inhibitors and omega-3 fatty acids and a combination product thereof
WO2007100807A2 (en) 2006-02-24 2007-09-07 Schering Corporation Npc1l1 orthologues
AR060623A1 (es) 2006-04-27 2008-07-02 Astrazeneca Ab Compuestos derivados de 2-azetidinona y un metodo de preparacion
US20070275052A1 (en) * 2006-05-24 2007-11-29 Glenmark Pharmaceuticals Limited Pharmaceutical compositions containing sterol inhibitors
WO2007150063A2 (en) * 2006-06-23 2007-12-27 Cargill Incorporated Compositions for lowering blood serum cholesterol and use in foods, beverages, and health supplements
US20080033019A1 (en) * 2006-08-07 2008-02-07 Duke University Cholesterol lowering drug combination
US20080085315A1 (en) * 2006-10-10 2008-04-10 John Alfred Doney Amorphous ezetimibe and the production thereof
ES2372652T3 (es) * 2007-05-23 2012-01-25 Amcol International Corporation Filosilicatos estratificados, que interactúan con el colesterol y métodos para reducir la hipercolesterolemia en un mamífero.
ES2639995T3 (es) 2007-12-10 2017-10-31 Ratiopharm Gmbh Formulación farmacéutica que comprende ezetimiba
EP2168573A1 (en) * 2008-09-30 2010-03-31 LEK Pharmaceuticals D.D. Formulations comprising ezetimibe
TWI522109B (zh) * 2009-01-26 2016-02-21 臺北醫學大學 蕨素化合物用於治療糖尿病及肥胖之用途
ES2382773T3 (es) 2009-03-13 2012-06-13 Sanovel Ilac Sanayi Ve Ticaret A.S. Composiciones de ezetimiba
CA2757722C (en) 2009-04-01 2018-05-22 Matrix Laboratories Ltd. Enzymatic process for the preparation of (s)-5-(4-fluoro-phenyl)-5-hydroxy- 1morpholin-4-yl-pentan-1-one, an intermediate of ezetimibe and further conversion to ezetimibe
TR200904500A2 (tr) 2009-06-10 2009-10-21 Öner Levent Ezetimib nanokristallerinin hazırlanması için yöntem ve farmasötik formülasyonları.
AU2013321918B2 (en) 2012-09-27 2018-05-10 Kowa Company, Ltd. Therapeutic agent for dyslipidemia
KR20150079373A (ko) 2013-12-30 2015-07-08 한미약품 주식회사 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제
CN104337785A (zh) * 2014-11-04 2015-02-11 万全万特制药江苏有限公司 一种含有依折麦布的口腔崩解片及其制备方法
CN105213340A (zh) * 2015-10-29 2016-01-06 无锡福祈制药有限公司 一种依折麦布片及其制备方法
JP2017210455A (ja) * 2016-05-27 2017-11-30 ニプロ株式会社 エゼチミブ含有医薬組成物
CN106310173A (zh) * 2016-08-24 2017-01-11 厦门三川利生物科技有限公司 含过氧化物酶体增殖物激活受体多维果酸醇及其制备方法
US20180338922A1 (en) 2017-05-26 2018-11-29 Esperion Therapeutics, Inc. Fixed dose formulations
EP3437636A1 (en) 2017-08-02 2019-02-06 Adamed sp. z o.o. Pharmaceutical composition comprising ezetimibe
CN109718215A (zh) * 2017-10-30 2019-05-07 海南皇隆制药股份有限公司 一种依折麦布片
KR101983298B1 (ko) * 2018-06-11 2019-05-29 연세대학교 산학협력단 인플라마좀 매개 염증성 질환의 예방 또는 치료용 약학 조성물

Family Cites Families (174)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3108097A (en) * 1963-10-22 Ehnojs
US2809194A (en) * 1957-10-08 Thiadiazine type natriuretic agents
US1286A (en) * 1839-08-13 Richard else
NL238796A (es) * 1958-05-07
NL127065C (es) * 1964-04-22
NL137318C (es) * 1964-06-09
FI52570C (fi) * 1969-04-16 1977-10-10 Sumitomo Chemical Co Menetelmä veren kolesteroli- tai lipoidipitoisuutta alentavien fenoxia lifaattisten karboksyylihappoyhdisteiden ja -esteriyhdisteiden valmist amiseksi.
US3692895A (en) * 1970-09-08 1972-09-19 Norman A Nelson Method of reducing hypercholesteremia in humans employing a copolymer of polyethylenepolyamine and a bifunctional substance, such as epichlorohydria
DE2230383C3 (de) * 1971-10-01 1981-12-03 Boehringer Mannheim Gmbh, 6800 Mannheim Phenoxyalkylcarbonsäurederivate und Verfahren zur Herstellung derselben
US4148923A (en) * 1972-05-31 1979-04-10 Synthelabo 1-(3'-Trifluoromethylthiophenyl)-2-ethylaminopropane pharmaceutical composition and method for treating obesity
US3948973A (en) * 1972-08-29 1976-04-06 Sterling Drug Inc. Halocyclopropyl substituted phenoxyalkanoic acids
US4626549A (en) * 1974-01-10 1986-12-02 Eli Lilly And Company Treatment of obesity with aryloxyphenylpropylamines
US4179515A (en) * 1975-02-12 1979-12-18 Orchimed S. A. Benzoylphenoxy propionic acid, esters thereof and pharmaceutical composition
US4235896A (en) * 1975-02-12 1980-11-25 Orchimed S.A. Benzyl-phenoxy acid esters and hyperlipaemia compositions containing the same
JPS5195049A (en) * 1975-02-12 1976-08-20 * **********so*****no***tsu*****************************************ni*no
US4075000A (en) * 1975-05-27 1978-02-21 Eli Lilly And Company Herbicidal use of 4-amino-3,3-dimethyl-1-phenyl-2-azetidinones
US4576753A (en) * 1975-10-06 1986-03-18 Fujisawa Pharmaceutical Co., Ltd. Azetidinone compounds and processes for preparation thereof
US4472309A (en) * 1975-10-06 1984-09-18 Fujisawa Pharmaceutical Co., Ltd. 2-Azetidinone compounds and processes for preparation thereof
US4304718A (en) * 1975-10-06 1981-12-08 Fujisawa Pharmaceutical Co., Ltd. 2-Azetidinone compounds and processes for preparation thereof
US4166907A (en) * 1976-11-01 1979-09-04 E. R. Squibb & Sons, Inc. 3,3-Dichloro-2-azetidinone derivatives having antiinflammatory activity
US4144232A (en) * 1976-12-23 1979-03-13 Eli Lilly And Company Substituted azetidin-2-one antibiotics
FR2403078A1 (fr) * 1977-09-19 1979-04-13 Lafon Labor Nouveau procede de preparation de formes pharmaceutiques, cosmetiques ou de diagnostic
IT1157365B (it) * 1977-10-24 1987-02-11 Sandoz Ag Medicamenti per trattare l'obesita' o ridurre il peso del corpo
US4250191A (en) * 1978-11-30 1981-02-10 Edwards K David Preventing renal failure
US4375475A (en) * 1979-08-17 1983-03-01 Merck & Co., Inc. Substituted pyranone inhibitors of cholesterol synthesis
US4260743A (en) * 1979-12-31 1981-04-07 Gist-Brocades N.V. Preparation of β-lactams and intermediates therefor
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
DE3107100A1 (de) * 1981-02-20 1982-09-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen Azaprostacycline, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung
US4500456A (en) * 1981-03-09 1985-02-19 Eli Lilly And Company Preparation of 4-fluoroazetidinones using FClO3
US4784734A (en) * 1981-04-10 1988-11-15 Otsuka Kagaku Yakuhin Kabushiki Kaisha Azetidinone derivatives and process for the preparation of the same
US4602003A (en) * 1982-05-17 1986-07-22 Medical Research Foundation Of Oregon Synthetic compounds to inhibit intestinal absorption of cholesterol in the treatment of hypercholesterolemia
US4602005A (en) * 1982-05-17 1986-07-22 Medical Research Foundation Of Oregon Tigogenin cellobioside for treating hypercholesterolemia and atherosclerosis
US4443372A (en) * 1982-06-23 1984-04-17 Chevron Research Company 1-Alkyl derivatives of 3-aryloxy-4-(2-carbalkoxy)-phenyl-azet-2-ones as plant growth regulators
US4534786A (en) * 1982-06-23 1985-08-13 Chevron Research Company 1-Alkyl derivatives of 3-aryloxy-4-(2-carbalkoxy)-phenyl-azet-2-ones as plant growth regulators
US4595532A (en) * 1983-02-02 1986-06-17 University Of Notre Dame Du Lac N-(substituted-methyl)-azetidin-2-ones
CA1256650A (en) * 1983-03-25 1989-06-27 Toshinari Tamura Process of producing 2-azetidinone-4-substituted compounds, and medicaments containing the compounds
US4675399A (en) * 1983-03-28 1987-06-23 Notre Dame University Cyclization process for β-lactams
DE3484362D1 (de) * 1983-03-28 1991-05-08 Ciba Geigy Ag Verfahren zur herstellung von optisch aktiven azetidinonen.
WO1985004876A1 (en) * 1984-04-24 1985-11-07 Takeda Chemical Industries, Ltd. 2-azetidinone derivatives and process for their preparation
US4576749A (en) * 1983-10-03 1986-03-18 E. R. Squibb & Sons, Inc. 3-Acylamino-1-carboxymethylaminocarbonyl-2-azetidinones
US5229510A (en) * 1983-12-01 1993-07-20 Merck & Co., Inc. β-lactams useful in determining the amount of elastase in a clinical sample
US5229381A (en) * 1983-12-01 1993-07-20 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
US4680391A (en) * 1983-12-01 1987-07-14 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
US4654362A (en) * 1983-12-05 1987-03-31 Janssen Pharmaceutica, N.V. Derivatives of 2,2'-iminobisethanol
FR2561916B1 (fr) * 1984-03-30 1987-12-11 Lafon Labor Forme galenique pour administration orale et son procede de preparation par lyophilisation d'une emission huile dans eau
US4633017A (en) * 1984-08-03 1986-12-30 E. R. Squibb & Sons, Inc. N-hydroxy protecting groups and process for the preparation of 3-acylamino-1-hydroxy-2-azetidinones
US4581170A (en) * 1984-08-03 1986-04-08 E. R. Squibb & Sons, Inc. N-hydroxyl protecting groups and process and intermediates for the preparation of 3-acylamino-1-hydroxy-2-azetidinones
US4576748A (en) * 1984-09-17 1986-03-18 Merck & Co., Inc. 3-Hydroxy-3-aminoethyl β-lactams
US4620867A (en) * 1984-09-28 1986-11-04 Chevron Research Company 1-carbalkoxyalkyl-3-aryloxy-4-(substituted-2'-carboxyphenyl)-azet-2-ones as plant growth regulators and herbicides
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
US4642903A (en) * 1985-03-26 1987-02-17 R. P. Scherer Corporation Freeze-dried foam dosage form
US4680289A (en) * 1985-06-05 1987-07-14 Progenics, Inc. Treatment of obesity and diabetes using sapogenins
EP0234484B1 (en) * 1986-02-19 1993-10-20 Sanraku Incorporated Novel azetidinone derivatives
GB8607312D0 (en) * 1986-03-25 1986-04-30 Ici Plc Therapeutic agents
FR2598146B1 (fr) * 1986-04-30 1989-01-20 Rech Ind Nouveau procede de preparation de fibrates.
DE3621861A1 (de) * 1986-06-30 1988-01-14 Laszlo Dr Med Ilg Verwendung von aryloxycarbonsaeure-derivaten gegen dermatologische erkrankungen
FR2602423B1 (fr) * 1986-08-08 1989-05-05 Ethypharm Sa Procede de preparation d'un medicament a base de fenofibrate, medicament obtenu par ce procede
US4814354A (en) * 1986-09-26 1989-03-21 Warner-Lambert Company Lipid regulating agents
US4803266A (en) * 1986-10-17 1989-02-07 Taisho Pharmaceutical Co., Ltd. 3-Oxoalkylidene-2-azetidinone derivatives
ZA879415B (en) 1986-12-15 1989-08-30 Lilly Co Eli Antibiotic a10255 complex and factors,microorganisms,process and production therefor
US5229362A (en) * 1986-12-15 1993-07-20 Eli Lilly And Company Antibiotic A10255 complex and factors, and process and production therefor
JPS63156788A (ja) * 1986-12-22 1988-06-29 Sanraku Inc 光学活性アゼチジノン類
US5110730A (en) * 1987-03-31 1992-05-05 The Scripps Research Institute Human tissue factor related DNA segments
DE3877406T2 (de) * 1987-04-28 1993-06-09 Fujisawa Astra Ltd Benzothiazolinon-derivate, ihre herstellung und pharmazeutische zusammensetzung.
US5106833A (en) * 1987-07-23 1992-04-21 Washington University Coagulation inhibitors
US5091525A (en) * 1987-10-07 1992-02-25 Eli Lilly And Company Monohydrate and DMF solvates of a new carbacephem antibiotic
US4834846A (en) * 1987-12-07 1989-05-30 Merck & Co., Inc. Process for deblocking N-substituted β-lactams
US5385885A (en) * 1988-01-15 1995-01-31 Gasic; Gregory P. Inhibition of smooth muscle cell proliferation by antistasin and tick anticoagulant peptide
FR2627696B1 (fr) * 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
DE3807895A1 (de) * 1988-03-10 1989-09-21 Knoll Ag Erzeugnisse, enthaltend einen calciumantagonisten und einen lipidsenker
GB8813012D0 (en) * 1988-06-02 1988-07-06 Norsk Hydro As Non-b-oxidizable fatty acid analogues to reduce concentration of cholesterol & triglycerides in blood of mammals
FR2634376B1 (fr) * 1988-07-21 1992-04-17 Farmalyoc Nouvelle forme unitaire, solide et poreuse comprenant des microparticules et/ou des nanoparticules, ainsi que sa preparation
US4952689A (en) * 1988-10-20 1990-08-28 Taisho Pharmaceutical Co., Ltd. 3-(substituted propylidene)-2-azetidinone derivates for blood platelet aggregation
CA1340977C (en) * 1988-11-15 2000-04-25 Monty Krieger Scavenger receptor protein and antibody thereto
US5112616A (en) * 1988-11-30 1992-05-12 Schering Corporation Fast dissolving buccal tablet
US5073374A (en) * 1988-11-30 1991-12-17 Schering Corporation Fast dissolving buccal tablet
US4876365A (en) * 1988-12-05 1989-10-24 Schering Corporation Intermediate compounds for preparing penems and carbapenems
US5260305A (en) 1988-12-12 1993-11-09 E. R. Squibb & Sons, Inc. Combination of pravastatin and nicotinic acid or related acid and method for lowering serum cholesterol using such combination
FR2640621B1 (fr) * 1988-12-19 1992-10-30 Centre Nat Rech Scient N-aryl-azetidinones, leur procede de preparation et leur utilisation comme inhibiteurs des elastases
US4990535A (en) * 1989-05-03 1991-02-05 Schering Corporation Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine
CA2016467A1 (en) 1989-06-05 1990-12-05 Martin Eisman Method for treating peripheral atherosclerotic disease employing an hmg coa reductase inhibitor and/or a squalene synthetase inhibitor
JPH03108490A (ja) * 1989-06-30 1991-05-08 Shionogi & Co Ltd フォスフォリパーゼａ↓２阻害物質
US5021461A (en) * 1989-07-26 1991-06-04 Merrell Dow Pharmaceuticals Inc. Method of treating diabetes mellitus with bisphenol derivatives
US4983597A (en) * 1989-08-31 1991-01-08 Merck & Co., Inc. Beta-lactams as anticholesterolemic agents
US5219574A (en) * 1989-09-15 1993-06-15 Cima Labs. Inc. Magnesium carbonate and oil tableting aid and flavoring additive
US5223264A (en) * 1989-10-02 1993-06-29 Cima Labs, Inc. Pediatric effervescent dosage form
US5178878A (en) * 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
US5188825A (en) * 1989-12-28 1993-02-23 Iles Martin C Freeze-dried dosage forms and methods for preparing the same
US5298497A (en) 1990-05-15 1994-03-29 E. R. Squibb & Sons, Inc. Method for preventing onset of hypertension employing a cholesterol lowering drug
US5622985A (en) * 1990-06-11 1997-04-22 Bristol-Myers Squibb Company Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
US5120729A (en) * 1990-06-20 1992-06-09 Merck & Co., Inc. Beta-lactams as antihypercholesterolemics
US5120713A (en) * 1990-09-10 1992-06-09 Applied Research Systems Ars Holding N.V. Treatment of obesity with an alpha-2-adrenergic agonist and a growth hormone releasing peptide
US5130333A (en) * 1990-10-19 1992-07-14 E. R. Squibb & Sons, Inc. Method for treating type II diabetes employing a cholesterol lowering drug
US5190970A (en) * 1990-10-19 1993-03-02 E. R. Squibb & Sons, Inc. Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor
JP2640986B2 (ja) * 1990-11-08 1997-08-13 高砂香料工業株式会社 （１′ｒ，３ｓ）―３―（１′―ヒドロキシエチル）―アゼチジン―２―オン又はその誘導体の製造法
IL100091A (en) * 1990-12-12 1998-08-16 Zeneca Ltd Pharmaceutical preparations containing the physical form of [4] 5) Cyclopentyloxycarbyl (amino 1 methyl indole 3 methyl methyl [3 methoxybenzoyl [2 methylbenzole)
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
AU642066B2 (en) 1991-01-25 1993-10-07 Nanosystems L.L.C. X-ray contrast compositions useful in medical imaging
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5157025A (en) * 1991-04-01 1992-10-20 E. R. Squibb & Sons, Inc. Method for lowering serum cholesterol employing a phosphorus containing ace inhibitor alone or in combination with a cholesterol lowering drug
MY131273A (en) 1991-07-23 2007-07-31 Schering Corp Substituted beta-lactam compounds useful as hypocholesterolemic agents and processes for the preparation thereof
US5162117A (en) * 1991-11-22 1992-11-10 Schering Corporation Controlled release flutamide composition
US5278176A (en) 1992-08-21 1994-01-11 Abbott Laboratories Nicotine derivatives that enhance cognitive function
AU660852B2 (en) * 1992-11-25 1995-07-06 Elan Pharma International Limited Method of grinding pharmaceutical substances
US5503846A (en) * 1993-03-17 1996-04-02 Cima Labs, Inc. Base coated acid particles and effervescent formulation incorporating same
US5412092A (en) * 1993-04-23 1995-05-02 Bristol-Myers Squibb Company N-substituted 2-azetidinones
ATE208615T1 (de) * 1993-07-09 2001-11-15 Scherer Corp R P Verfahren zur herstellung von gefriergetrockneten arzneistoffdosierungsformen
ATE205475T1 (de) * 1993-07-09 2001-09-15 Schering Corp Verfahren zur herstellung von azetidinonen
US5622719A (en) * 1993-09-10 1997-04-22 Fuisz Technologies Ltd. Process and apparatus for making rapidly dissolving dosage units and product therefrom
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5595761A (en) * 1994-01-27 1997-01-21 The Board Of Regents Of The University Of Oklahoma Particulate support matrix for making a rapidly dissolving tablet
US5627176A (en) * 1994-03-25 1997-05-06 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
TW384224B (en) * 1994-05-25 2000-03-11 Nano Sys Llc Method of preparing submicron particles of a therapeutic or diagnostic agent
US5718388A (en) * 1994-05-25 1998-02-17 Eastman Kodak Continuous method of grinding pharmaceutical substances
MX9606319A (es) * 1994-06-20 1997-05-31 Schering Corp Compuestos de acetidinonas sustituidas utiles como agentes hipocolesterolemicos.
US5633246A (en) * 1994-11-18 1997-05-27 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5624920A (en) * 1994-11-18 1997-04-29 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
FR2730231B1 (fr) * 1995-02-02 1997-04-04 Fournier Sca Lab Association de fenofibrate et de vitamine e, utilisation en therapeutique
US5639475A (en) * 1995-02-03 1997-06-17 Eurand America, Incorporated Effervescent microcapsules
US5518738A (en) * 1995-02-09 1996-05-21 Nanosystem L.L.C. Nanoparticulate nsaid compositions
US5591456A (en) * 1995-02-10 1997-01-07 Nanosystems L.L.C. Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
JP3144624B2 (ja) * 1995-06-02 2001-03-12 杏林製薬株式会社 Ｎ−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
US5612378A (en) * 1995-06-06 1997-03-18 3-Dimensional Pharmaceuticals, Inc. Bis-arylsulfonylaminobenzamide derivatives and the use thereof as factor Xa inhibitors
US5607697A (en) * 1995-06-07 1997-03-04 Cima Labs, Incorporated Taste masking microparticles for oral dosage forms
US5612353A (en) * 1995-06-07 1997-03-18 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) N-[(aminoiminomethyl)phenylalkyl]-azaheterocyclylamide compounds
FR2738817B1 (fr) * 1995-09-14 1997-10-17 Adir Nouveaux acides et esters 2,2-dimethyl-omega-phenoxy alcanoiques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US5618707A (en) * 1996-01-04 1997-04-08 Schering Corporation Stereoselective microbial reduction of 5-fluorophenyl-5-oxo-pentanoic acid and a phenyloxazolidinone condensation product thereof
WO1997016424A1 (en) * 1995-11-02 1997-05-09 Schering Corporation Process for preparing 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-([phenyl or 4-fluorophenyl])-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinone
GB9600464D0 (en) * 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
US5859051A (en) * 1996-02-02 1999-01-12 Merck & Co., Inc. Antidiabetic agents
GB9606805D0 (en) * 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
JP2000508659A (ja) * 1996-04-17 2000-07-11 メルク エンド カンパニー インコーポレーテッド 心血管疾患関連の危険性を低減する組み合わせ療法
US5858409A (en) * 1996-04-17 1999-01-12 Fmc Corporation Hydrolyzed cellulose granulations for pharmaceuticals
BR9711167A (pt) * 1996-05-24 1999-08-17 Schering Corp Composi-Æo antifÚngica com maior biodisponibilidade
US5739321A (en) * 1996-05-31 1998-04-14 Schering Corporation 3-hydroxy γ-lactone based enantionselective synthesis of azetidinones
US5886171A (en) * 1996-05-31 1999-03-23 Schering Corporation 3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones
WO1997047209A1 (fr) * 1996-06-12 1997-12-18 Kyowa Hakko Kogyo Co., Ltd. Amelioration du metabolisme lipidique
US5883109A (en) * 1996-07-24 1999-03-16 Bristol-Myers Squibb Company Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
FR2761266B1 (fr) * 1997-03-28 1999-07-02 Sanofi Sa Composition pharmaceutique formee par granulation humide pour l'administration orale d'un derive du n-piperidino-3- pyrazolecarboxamide, de ses sels et de leurs solvates
PT1003501E (pt) * 1997-04-02 2005-07-29 Brigham & Womens Hospital Utilizacao de um agente para reduzir o risco de doencas cardiovasculares
ES2125198B1 (es) * 1997-05-13 1999-11-16 Vita Invest Sa Asociacion a dosis fija de un inhibidor de la enzima convertidora de angiotensina y de un antagonista de los canales de calcio, procedimiento para su preparacion y su utilizacion para el tratamiento de enfermees cardiovasculares.
US5886191A (en) * 1997-08-18 1999-03-23 Dupont Pharmaceuticals Company Amidinoindoles, amidinoazoles, and analogs thereof
US5869098A (en) * 1997-08-20 1999-02-09 Fuisz Technologies Ltd. Fast-dissolving comestible units formed under high-speed/high-pressure conditions
AR016827A1 (es) * 1997-08-22 2001-08-01 Smithkline Beecham Corp PROCEDIMIENTO PARA LA PREPARACIoN DE UNA TABLETA FARMACÉUTICA
US6180660B1 (en) * 1997-08-26 2001-01-30 Merck & Co., Inc. Cholesterol-lowering therapy
EP1015429B1 (en) * 1997-09-09 2004-05-12 Bristol-Myers Squibb Pharma Company Benzimidazolinones, benzoxazolinones, benzopiperazinones, indanones, and derivatives thereof as inhibitors of factor xa
US20030153541A1 (en) * 1997-10-31 2003-08-14 Robert Dudley Novel anticholesterol compositions and method for using same
US6027747A (en) * 1997-11-11 2000-02-22 Terracol; Didier Process for the production of dry pharmaceutical forms and the thus obtained pharmaceutical compositions
US6008237A (en) * 1997-12-19 1999-12-28 Merck & Co., Inc. Arylthiazolidinedione derivatives
US6180625B1 (en) * 1998-03-24 2001-01-30 Novo Nordisk A/S Heterocyclic compounds regulating clotting
DE69920888T2 (de) * 1998-03-27 2006-02-02 Bristol-Myers Squibb Pharma Co. Disubstituierte pyrazoline und triazoline als faktor xa inhibitoren
WO1999008501A2 (en) * 1998-04-23 1999-02-25 Dr. Reddy's Research Foundation New heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
US6207822B1 (en) * 1998-12-07 2001-03-27 Schering Corporation Process for the synthesis of azetidinones
EP1140187B1 (en) * 1998-12-23 2003-09-03 G.D. Searle LLC. Combinations of an ibat inhibitor and a mtp inhibitor for cardiovascular indications
US6180138B1 (en) * 1999-01-29 2001-01-30 Abbott Laboratories Process for preparing solid formulations of lipid-regulating agents with enhanced dissolution and absorption
US6033656A (en) * 1999-05-04 2000-03-07 Sumitomo Chemical Company, Limited Method of preventing or alleviating mammalian obesity
US6207699B1 (en) * 1999-06-18 2001-03-27 Richard Brian Rothman Pharmaceutical combinations for treating obesity and food craving
US6174665B1 (en) * 1999-09-10 2001-01-16 Biex, Inc. Hormone replacement therapy monitoring
DK1175220T3 (da) * 1999-12-08 2005-08-29 Pharmacia Corp Nanopartikulære eplerenonkompositioner
US6191117B1 (en) * 2000-07-10 2001-02-20 Walter E. Kozachuk Methods of producing weight loss and treatment of obesity
US20020132855A1 (en) * 2000-08-03 2002-09-19 Nelson Edward B. Use of acetaminophen to prevent and treat arteriosclerosis
DE10042447A1 (de) * 2000-08-29 2002-03-28 Aventis Pharma Gmbh Protein aus dem Darm von Wirbeltieren, welches Cholesterin absorbiert, sowie Verwendung dieses Proteins zur Identifizierung von Inhibitoren des intestinalen Cholesterintransports
JP2004513090A (ja) * 2000-09-27 2004-04-30 メルク　エンド　カムパニー　インコーポレーテッド 糖尿病及び脂質異常症の治療のためのベンゾピランカルボン酸誘導体
AU2002216097B2 (en) * 2000-12-21 2006-09-07 Sanofi-Aventis Deutschland Gmbh Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism
IL156552A0 (en) * 2000-12-21 2004-01-04 Aventis Pharma Gmbh Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
AU2002231688A1 (en) * 2000-12-21 2002-07-01 Sanofi-Aventis Deutschland Gmbh Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
AR035739A1 (es) * 2001-01-26 2004-07-07 Schering Corp Composiciones farmaceuticas y combinaciones terapeuticas que comprenden secuestrante (s) de los acidos biliares y de inhibidor (es) de la absorcion de los esteroles y el uso de dichas composiciones para la manufactura de un medicamento para el tratamiento de indicaciones vasculares
JP2004517919A (ja) * 2001-01-26 2004-06-17 シェーリング　コーポレイション 血管状態の処置のための心臓血管薬剤とステロール吸収インヒビターとの組み合わせ
AU2002251978B2 (en) * 2001-02-09 2007-07-19 Merck & Co., Inc. 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders
EP1389114A2 (en) * 2001-03-08 2004-02-18 Merck & Co., Inc. Antihypertensive agent and cholesterol absorption inhibitor combination therapy
WO2002081454A1 (en) * 2001-04-09 2002-10-17 Dr. Reddy's Laboratories Ltd. Derivatives of aryl acids, their use in medicine, process for their preparation and pharmaceutical compositions containing them
US7348334B2 (en) * 2001-04-09 2008-03-25 Dr. Reddy's Laboratories Limited Monocyclic derivatives of aryl alkanoic acids and their use in medicine: process for their preparation and pharmaceutical compositions containing them
PT1392287E (pt) * 2001-05-25 2007-02-28 Schering Corp Métodos para tratamento de doença de alzheimer e/ou regulação dos níveis de peptídeos β amilóide num sujeito

Also Published As

Publication number Publication date
CN100509058C (zh) 2009-07-08
CA2562982A1 (en) 2002-08-01
IL156445A0 (en) 2004-01-04
HK1056696A1 (en) 2004-02-27
SI1353696T1 (sl) 2007-04-30
MEP27808A (en) 2010-10-10
JP2008088184A (ja) 2008-04-17
IL191417A (en) 2011-12-29
CY1108000T1 (el) 2013-09-04
JP4777602B2 (ja) 2011-09-21
SK9482003A3 (en) 2003-12-02
SK288217B6 (sk) 2014-08-05
JP4937836B2 (ja) 2012-05-23
RS51449B (sr) 2011-04-30
ES2290562T3 (es) 2008-02-16
YU58603A (sh) 2006-05-25
RU2003126184A (ru) 2005-03-10
ZA200305693B (en) 2005-04-26
PL208110B1 (pl) 2011-03-31
WO2002058732A3 (en) 2003-07-03
DE60222773T2 (de) 2008-07-17
EP1413331B1 (en) 2007-10-03
CA2434682A1 (en) 2002-08-01
NO20033355D0 (no) 2003-07-25
DE60216890T2 (de) 2007-08-30
NO20033355L (no) 2003-07-25
DE60216890D1 (de) 2007-02-01
TWI337083B (en) 2011-02-11
JP2007211031A (ja) 2007-08-23
AU2002247019B2 (en) 2006-08-03
WO2002058732A2 (en) 2002-08-01
KR20040025887A (ko) 2004-03-26
BR0206654A (pt) 2004-02-25
CL2004001174A1 (es) 2005-05-06
PT1413331E (pt) 2007-12-18
DK1353696T3 (da) 2007-04-10
US20020151536A1 (en) 2002-10-17
CA2434682C (en) 2008-11-18
IL156445A (en) 2010-11-30
CA2562982C (en) 2011-03-15
EP1413331A3 (en) 2004-06-30
EP1353696A2 (en) 2003-10-22
PL368653A1 (en) 2005-04-04
US7030106B2 (en) 2006-04-18
HUP0303915A2 (hu) 2004-03-01
EP1413331A2 (en) 2004-04-28
DE60222773D1 (de) 2007-11-15
WO2002058732B1 (en) 2003-09-12
EP1353696B1 (en) 2006-12-20
HUP0303915A3 (en) 2012-12-28
US7612058B2 (en) 2009-11-03
ATE374641T1 (de) 2007-10-15
CZ301871B6 (cs) 2010-07-14
MXPA03006725A (es) 2003-10-24
DK1413331T3 (da) 2007-12-10
HU230253B1 (hu) 2015-11-30
HK1063607A1 (en) 2005-01-07
US20050153952A1 (en) 2005-07-14
CZ309209B6 (cs) 2022-05-25
JP2012087149A (ja) 2012-05-10
NZ525921A (en) 2005-06-24
US20080058306A1 (en) 2008-03-06
AU2002247019C1 (en) 2017-05-11
US20060199793A1 (en) 2006-09-07
JP2004521893A (ja) 2004-07-22
US20020192203A1 (en) 2002-12-19
SK287988B6 (sk) 2012-09-03
CN1646165A (zh) 2005-07-27
PT1353696E (pt) 2007-02-28
SI1413331T1 (sl) 2008-02-29
RU2356550C2 (ru) 2009-05-27
CZ2010307A3 (es) 2004-01-14
RS20100015A (en) 2010-12-31
KR100596257B1 (ko) 2006-07-03
ATE348649T1 (de) 2007-01-15
CA2563051A1 (en) 2002-08-01
CY1107045T1 (el) 2012-09-26
RU2008144912A (ru) 2010-05-20
ES2274013T3 (es) 2007-05-16
CZ20032030A3 (cs) 2004-01-14
NO331512B1 (no) 2012-01-16
AR033855A1 (es) 2004-01-07
ECSP11004702A (es) 2011-03-31

Similar Documents

Publication Publication Date Title
AR064012A2 (es) Composiciones y combinaciones de activador(es) del receptor de activacion de proliferacion peroxismal (ppar) e inhibidor(es) de absorcion de esterol el uso de dichas composiciones para la manufactura de un medicamento para el tratamiento para indicaciones vasculares diabetes obesidad o reduccion de
US6362190B2 (en) Method for treating inflammatory diseases by administering a thrombin inhibitor
NO20076319L (no) Farmasoytiske sammensetninger av et neuroaktivt steroid og anvendelse derav
BR0314308A (pt) Composto, composição farmacêutica, métodos para bloquear uma combinação de mu, kappa, delta ou receptor (heterodìmero) dos mesmos em mamìferos, para tratar ou prevenir obesidade e doenças relacionadas, para suprimir o apetite em um paciente em necessidade deste, e para realizar a perda de peso em um paciente obeso, e, uso de um composto
NO20091938L (no) 7,8-dihydro-1,6-naftyridin-5(6H)-oner og relaterte bicykliske forbindelser som inhibitorer av dipeptidyl-peptidaser IV og metoder
NO20040301L (no) Novel pyrroles having hypolipidemic hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them and their use in medicine
BR9912866A (pt) Composto ou uma forma tautomérica, sal ousolvato farmaceuticamente aceitável do mesmo,composição farmacêutica, processo para otratamento ou a prevenção de uma doença, fatorde risco ou condição, mediada por hppar alfa e/ouhppar gama, e uso de um composto
AR041089A1 (es) Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
CR9842A (es) Composiciones de celecoxib
DE60330187D1 (de) Fluoralkoxy-substituierte 1, 3-dihydro-isoindolyl-verbindungen und ihre pharmazeutischen verwendungen
BRPI0513824A (pt) derivados glucitol, seu pró-fármaco e seu sal e agente terapêutico contendo os mesmos para diabetes
BR0111034A (pt) Composto, composição farmacêutica, uso de um composto, e, métodos para o tratamento ou profilaxia de condições ou doenças inflamatórias, para o tratamento e/ou profilaxia de osteoporose e para o tratamento de doenças relacionadas à aids
MXPA04007414A (es) Indoles sustituidos como agonistas alfa-1.
TW200607807A (en) Macrocyclic beta-secretase inhibitors
TW200621249A (en) Substituted amide beta secretase inhibitors
BRPI0513384A (pt) combinação de inibidores de dpp-iv e compostos que modulam receptores de 5-ht3 e/ou 5-ht4
NO20082445L (no) Neuropeptid-2 reseptor-agonister
MXPA04005156A (es) Antagonistas del receptor de adenosina a2a.
BRPI0509074A (pt) composições farmacêuticas compreendendo agonistas do receptor da tiróide
WO2004017896A3 (en) Combination therapy using a dual ppar alpha/gamma agonist and an angiotensin ii type i receptor antagonist
GB0324654D0 (en) Medicinal compounds
BR0313148A (pt) Formulações de liberação controlada compreendendo lamotrigina
BRPI0518785A2 (pt) composto de anel de 7 membros e mÉtodo de produÇço e aplicaÇço farmacÊutica do mesmo
CL2010000387A1 (es) Composicion farmaceutica que comprende sal de acido lactico de un derivado de quinolina en un 50% a 80% en relacion al peso total y al menos dos ingredientes mas; procedimiento de preparacion; kit farmaceutico; util en el tratamiento del cancer (dividisional de la solicitud 3324-06).
EP1784173A4 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING METABOLIC BONE DISEASES CONTAINING ALPHA-ARYLMETHOXYACRYLATE DERIVATIVES

Legal Events

Date Code Title Description
FB Suspension of granting procedure